| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Revenue | $0 | — |
| R&D Expense | $13.0M | -35.3% |
| SG&A Expense | $15.5M | -18.5% |
| Operating Income | -$31.2M | +30.2% |
| Interest Expense | $0 | -100.0% |
| Net Income | -$26.0M | +34.8% |
| EPS (Basic) | -$1.54 | +43.0% |
| EPS (Diluted) | -$1.54 | +43.0% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $7.6M | -61.7% |
| Short-term Investments | $15.7M | -33.1% |
| Current Assets | $24.3M | -47.9% |
| Total Assets | $37.7M | -42.7% |
| Current Liabilities | $9.3M | +18.1% |
| Total Liabilities | $31.2M | -16.4% |
| Stockholders' Equity | $6.5M | -77.1% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$20.9M | +43.7% |
| Capital Expenditures | $0 | -100.0% |
| Investing Cash Flow | $8.6M | -85.8% |
| Financing Cash Flow | $77K | +100.5% |
| Free Cash Flow | -$20.9M | +43.8% |